Liraglutide

• Liraglutide caused thyroid C-cell tumors in rodents. It is unknown whether this occurs in humans.
• Do NOT use liraglutide if you or your family have a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Seek medical attention if you experience a neck lump, hoarseness, trouble swallowing, or shortness of breath.

• Inject once daily under the skin (abdomen, thigh, or upper arm).
• Do NOT inject into a vein or muscle. Rotate injection sites daily.
• Increase dose gradually as directed to minimize nausea.
• Can be taken at any time of day, with or without food.
• Use a new needle for each injection. Never share pens or needles.

• Personal or family history of MTC or MEN 2.
• History of serious allergic reaction to liraglutide or product ingredients.
• Pregnant or breastfeeding individuals.
• Children unless prescribed for a specific indication.
• Those with severe gastrointestinal disease (e.g., gastroparesis).

• Pancreatitis: Discontinue immediately if severe abdominal pain radiating to the back occurs.
• Gallbladder Disease: Liraglutide can increase the risk of gallstones and cholecystitis.
• Kidney Function: Nausea, vomiting, or dehydration may worsen kidney problems; monitor renal function.
• Heart Rate: Liraglutide can increase resting heart rate; use caution in patients with cardiac conditions.
• Hypoglycemia: Especially when used with insulin or sulfonylureas—monitor blood sugar closely.
• Suicidal Thoughts: Monitor for mood or behavior changes, particularly during dose adjustments.
• Dehydration: Persistent vomiting or diarrhea can cause dehydration—maintain fluid intake.

• May delay absorption of oral medications due to slower gastric emptying.
• Use caution with insulin, sulfonylureas, or other glucose-lowering agents—risk of hypoglycemia.
• Consult your provider before combining with other GLP-1 receptor agonists or DPP-4 inhibitors.
• May interact with medications that affect appetite or GI motility.

Most Common: Nausea, vomiting, diarrhea, constipation, stomach pain, decreased appetite.

Moderate: Headache, dizziness, fatigue, indigestion, mild heartburn.

Serious (Seek Care Immediately):

• Severe stomach or back pain (possible pancreatitis).
• Yellowing of skin or eyes, dark urine (possible gallbladder or liver issue).
• Swelling of face, tongue, or throat; difficulty breathing (allergic reaction).
• Fast heartbeat, fainting, or severe dehydration.

• Pregnancy: Liraglutide is not recommended. Weight loss offers no benefit during pregnancy and may harm the fetus.
• Breastfeeding: Unknown if excreted in breast milk; not recommended while nursing.
• Older adults: Use caution—sensitivity to nausea or dehydration may be increased.
• Children: Safety not established for weight management use in pediatric populations.

• Store unopened pens in the refrigerator (36–46°F / 2–8°C).
• After first use: may store at room temperature (up to 86°F / 30°C) or refrigerated for up to 30 days.
• Do not freeze or expose to direct heat or sunlight.
• Keep pen capped and out of reach of children.